IGF1R and neoplasm: On the basis of former results of IGF-1R expression of primary site or possible circulating tumour cells in many cancers, targeting therapy with IGF-1R antibody was enormously developed within recent years (Bradley and Douglas, 2005; Gotlieb et al, 2006; de Bono et al, 2007; Hartog et al, 2007; Imsumran et al, 2007).